1. Home
  2. News
  3. Imugene Ltd
  4. First cohort 3 patient dosed in clinical trial of CHECKvacc
More Imugene Ltd news
Imugene LtdASX: IMU

First cohort 3 patient dosed in clinical trial of CHECKvacc

Aug 9, 2022 at 11:38 PM EDT · Issued by Imugene Ltd

Filed with ASX · Aug 9, 2022 at 11:38 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/first-cohort-3-patient-dosed-in-clinical-trial-of-checkvacc

Imugene Ltd on 6ix

Story so far

  • Dose Escalation in Phase 1 Clinical Trial of CHECKvaccMar 24, 2022
  • Update on Clinical Trial of Oncolytic Virotherapy CHECKvaccDec 7, 2021
  • First patient dosed in Phase I clinical trial of CHECKvaccOct 20, 2021

Earlier from Imugene

  • Imugene Presents New PD1-Vaxx Data at the 2022 WCLCAug 7, 2022
  • Final HER-Vaxx Phase 2 Trial Overall Survival ResultsJun 26, 2022
  • Imugene doses first patient in VAXINIA Phase 1 trialMay 17, 2022
  • IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZONMay 9, 2022
  • Clarification AnnouncementMay 3, 2022

Later from Imugene

  • Annual Report and Appendix 4EAug 30, 2022
  • Imugene Dose Escalates in Phase I Clinical Trial of VAXINIAAug 31, 2022
  • Imugene doses first patient in nextHERIZON Phase 2 trialSep 7, 2022
  • Imugene announces a$80 million institutional placementSep 12, 2022
  • Prospectus for the issue of institutional placement optionsSep 16, 2022
All Imugene news releases↗

Follow Imugene into a list and get an email when it puts out news.

Follow Imugene
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer